Corrigendum: CYP3A genetic variation and taxane-induced peripheral neuropathy: a systematic review, meta-analysis, and candidate gene study

Autor: Laurence McEvoy, Joanne Cliff, Daniel F Carr, Andrea Jorgensen, Rosemary Lord, Munir Pirmohamed

Publikováno v: Frontiers in Pharmacology, Vol 14 (2023)

Externí odkaz: https://doaj.org/article/a3c8e82000e0421da1091e42cd43e71c

6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE) : 4-year disease-free survival results of a randomised phase 3 non-inferiority trial

Autor: Jane Brown, Roshan Agarwal, Catherine Harper-Wynne, A. Humphreys, Eliot Sims, Peter Hall, Mukesh Mukesh, Sundus Yahya, Nawaz Walji, Mojca Persic, Donna L. Howe, Simon Waters, Wendy Taylor, Anita Chhabra, Karen Tipples, Helen Innes, Mark Churn, Peter Ostler, Pamela Woodings, Helen Roe, Lisa H Barraclough, Shrushma Loi, Maggie Wilcox, Susan Lupton, Adrian Harnett, Rebecca Bowen, Peter Simmonds, Natasha Mithal, H. M. Earl, Apurna Jegannathen, Kathryn Wright, A.S. Dhadda, Rozenn Allerton, Jean Abraham, Karen McAdam, Ioannis Gounaris, Mohini Varughese, Mark Harries, Helen Neville-Webbe, Catherine Bale, Narottam Thanvi, Carolyn Bedi, Carlos Caldas, Fharat A. Raja, Helena M. Earl, David Miles, Trevor McGolick, Andrew D. Goodman, Kerry Raynes, Anthony Neal, Richard Simcock, Hartmut Kristeleit, Carol MacGregor, Christopher McCabe, Caroline Archer, Laura Pettit, Chris Bradley, Anne-Laure Vallier, Urmila Barthakur, Perric Crellin, S O'Reilly, Betania Mahler Araujo, Andrew Eichholz, Louise Hiller, Anne Rigg, Janine Mansi, Jacqueline Newby, Janet A. Dunn, Sarah Smith, Chris Plummer, Jennifer Marshall, Aian Moss, Zafar Malik, Larry Hayward, Mohammad Butt, Andrew M Wardley, Anup Vinayan, Shiroma De Silva-Minor, Mei-Lin Ah-See, Sue Down, Helen B Higgins, Catherine Reed, Kim Benstead, Rakesh Mehra, Luke Hughes-Davies, David Cameron, Daniel Nelmes, O.S. Din, Charlotte Moss, Daniel Epurescu, Anne C Armstrong, Nicola Storey, David J. Eaton, Hafiz Algurafi, Mariam Jafri, Daniel Rea, Nihal Shah, Elena Provenzano, Susan Cleator, Muireann Kelleher, Claire Hulme, Daniela Lee, D. Bloomfield, Margaret Daly, Joanne Cliff, Chee Goh, Sanjay Raj, Maher Hadaki, Jayant S. Vaidya, Robert Grieve

Publikováno v: Earl, H M, Hiller, L, Vallier, A-L, Loi, S, McAdam, K, Hughes-Davies, L, Harnett, A N, Ah-See, M-L, Simcock, R, Rea, D, Raj, S, Woodings, P, Harries, M, Howe, D, Raynes, K, Higgins, H B, Wilcox, M, Plummer, C, Mansi, J, Gounaris, I, Mahler-Araujo, B, Provenzano, E, Chhabra, A, Abraham, J E, Caldas, C, Hall, P S, McCabe, C, Hulme, C, Miles, D, M Wardley, A & Cameron, D A & Dunn, J A 2019, ' 6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial ', The Lancet, vol. 393, no. 10191, pp. 2599-2612 . https://doi.org/10.1016/S0140-6736(19)30650-6
Lancet (London, England)

Background: Adjuvant trastuzumab significantly improves outcomes for patients with HER2-positive early breast cancer. The standard treatment duration is 12 months but shorter treatment could provide similar efficacy while reducing toxicities and cost

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bd37138df2c42b14428f44dc7b4ec95b
http://wrap.warwick.ac.uk/118352/2/WRAP-6-versus-12-months-adjuvant-trastuzumab-HER2-positive-early-breast-cancer(PERSEPHONE)-Dunn-2019.pdf

Real-world data regarding the efficacy of neoadjuvant carboplatin-paclitaxel followed by dose-dense adriamycin-cyclophosphamide for triple-negative early breast cancer

Autor: Helen Flint, Allison Hall, Carlo Palmieri, Douglas Errington, Silvia Cicconi, Zaf Malik, Julie O'Hagen, Joanne Cliff, Helen Wong, Benjamin Hall, Helen Innes, Ajay Ashok Bhojwani, Nicky Thorp, Andrea Law, Richard J. Jackson, Eliyaz Ahmed, Farida Alam, S O'Reilly, Shaun Tolan, Khizar Hayat

Publikováno v: Journal of Clinical Oncology. 37:e12559-e12559

e12559 Background: Platinum based regimens in the neoadjuvant (NA) setting for triple negative breast cancer (TNBC) have resulted in a significant increase in the pathological response (pCR) rate but at the cost of worse hematological toxicities. Des

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::7e66fda7a62e5f9cfb4380c3b99d389c
https://doi.org/10.1200/jco.2019.37.15_suppl.e12559

Are trans-national Professional Development Programmes doomed to fail to influence student outcomes?

Autor: Karen Hudson, David Littlefair, Joanne Clifford-Swanc

Publikováno v: JETEN, Vol -15, Iss 2020, Pp 30-42 (2020)

Trans-national education is increasing (Mahony, 2014) and with regard to professional development for teachers, is an important aspect of upskilling teachers to deliver high quality learning experiences for their pupils. This paper is concerned with

Externí odkaz: https://doaj.org/article/6f9b3a97298a45a7b8d2d6db9a7d7b86